While most practice-changing NSCLC CPI studies have tended to exclude EGFR and ALK positive patients, a subgroup analysis of the IMpower-150 trial stands alone in describing benefit for EGFR-mutant patients to a CPI-based regimen [27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.